In this file
A business can have public contact information, offer access to clinicians, and still face serious questions about the claims made for its products. Evaluating MEDVi requires looking at both the service documents and the regulatory record.
This file distinguishes company identity from product approval and personal treatment suitability. It does not give a blanket certification to the company or declare every service fraudulent.
What establishes a business to examine
MEDVi markets online prescription services, but the FDA’s February 20, 2026 warning letter is an essential independent document. It addresses claims involving unapproved GLP-1 drugs. An identifiable business and a prescribing pathway do not resolve the concerns described in that letter.
The published telephone number for MEDVi is (323) 690-1564. An email route appears at help@medvi.org.
Obtain the legal name on the agreement and the statement descriptor before paying. Those records identify a transaction but do not establish all corporate, licensing, or clinical facts.
What the FDA record adds
The warning letter dated February 20, 2026 addresses MEDVi’s compounded GLP-1 marketing and claims. A warning letter is an official regulatory document, not an anonymous review; its particular wording and scope should be read directly.
We do not infer that every possible later issue has been resolved or that the letter evaluates every product on every MEDVi site. The research here does not establish a company-wide regulatory clearance.
What remains prescription-specific
The public partner list includes Triad Rx, Red Rock, and Beaker. That list is a lead for questions, rather than confirmation of the pharmacy selected for a patient. The assigned dispenser and formulation still need to be identified.
Ask which clinician and pharmacy are responsible for your case. An approved ingredient or licensed pharmacy does not confer approval on a compounded preparation.
What remains contract-specific
The captured weight-loss material did not support one dependable all-in current price for every MEDVi plan. Its QUAD per-dose advertising concerns a different product category. For weight management, request the named medication, supply period, care charges, and the amount taken at renewal.
MEDVi provides links to legal and refund material, but not every legal destination could be established from the accessible evidence. Obtain the actual terms for the offer. Do not infer a refund right from a review, a guarantee headline, or an unanswered cancellation message.
Keep the connected details together
The MEDVi provider file connects the cost details, support routes, and cancellation questions so that the same plan can be checked from more than one angle.
How do the current offer and product claims address the issues in the FDA letter, and what precise medication would be supplied?
What the research does and does not show
This file follows published documents. It is not a mystery-shopper report, an inspection of a pharmacy, or a guarantee about a future patient experience. The dates and limitations in the source notes matter when a page or policy changes.
A clinician must assess personal treatment suitability. Our pre-purchase questions can help you record the information still needed before accepting an offer.
Source notes
Provider material describes the company’s own offer. Official medical references explain clinical and regulatory context; they do not endorse this publication or its commercial partner.
- MEDVi: provider, pharmacy, and contact disclosures ↗Provider-published information · Checked September 22, 2026
- FDA: MEDVi warning letter, February 20, 2026 ↗Regulatory / public agency · Checked September 22, 2026
- MEDVi QUAD: product and ingredient page ↗Provider-published information · Checked September 22, 2026
- FDA: risks of compounded drugs ↗Regulatory / public agency · Checked September 22, 2026
- FDA BeSafeRx: checking online pharmacies ↗Regulatory / public agency · Checked September 22, 2026
- FDA: concerns with unapproved GLP-1 drugs ↗Regulatory / public agency · Checked September 22, 2026